6 April 2017
Clinical Labs invests in new technology in the fight against diabetes.
Detection and regular monitoring are crucial in the fight against diabetes, one of the most prevalent diseases in Australia and developed countries. With the number of diabetes sufferers growing, Clinical Labs has invested in cutting edge technology to keep pace with this increasing trend and provide a faster and improved service to doctors and their patients.
Clinical Labs has invested in cutting edge technology with the acquisition of the Roche Cobas c513 Analyser, a dedicated instrument that performs HbA1c testing to monitor glucose levels in the fight against diabetes. The analyser has increased testing capacity and broader scope.
Clinical Labs Chemical Pathologist Dr David Deam said “The Roche Cobas c513 enables us to perform double the number of tests per hour.”
”This is important as HbA1c is the current standard measure for the diagnosis and clinical management of diabetes.”
Find out how you can monitor your patients’ diabetes more closely and create better outcomes through Clinical Labs Diabetes Evaluation Program.